Is CSL (ASX:CSL) Cheap On Tavneos Revocation Risk?

Simply Wall St.07-02

CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648021795?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-07-02 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648021795","market":"nz","top_or_hot":-1,"title":"Is CSL (ASX:CSL) Cheap On Tavneos Revocation Risk?","media":"Simply Wall St.","content":"<div>\n<p>CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-tavneos-revocation-risk\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is CSL (ASX:CSL) Cheap On Tavneos Revocation Risk?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs CSL (ASX:CSL) Cheap On Tavneos Revocation Risk?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 16:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-tavneos-revocation-risk><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-tavneos-revocation-risk\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0728928796.USD","symbol_name":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-tavneos-revocation-risk","article_id":"2648021795","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-tavneos-revocation-risk","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648021795","pubTimestamp":1782981994,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit and the stock’s recent recovery.\nSee our latest analysis for CSL.\nThe Tavneos setback arrives after a sharp 27.21% 1 month share price return for CSL. However, this sits against a weaker backdrop, with the stock down 31.52% year to date and the 1 year total shareholder return declining 49.94%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7501":"新冠治疗股","CSL":"卡莱尔伙伴","BK4086":"建筑产品","BK7511":"ESG概念","CSL.AU":"CSL LIMITED","BK7067":"生物科技","BK7508":"医药生物股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"CSL(ASX：CSL)的Tavneos撤销风险便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit and the stock’s recent recovery. See our latest analysis for CSL. The Tavneos setback arrives after a sharp 27.21% 1 month share price return for CSL. However, this sits against a weaker backdrop, with the stock down 31.52% year to date and the 1 year total shareholder return declining 49.94%, indicating fading longer term momentum despite the recent bounce. If this kind of regulatory twist has you rethinking where you want exposure in healthcare, it could be a good moment to scan other opportunities using our screener for 9 healthcare AI stocks So with CSL shares rebounding 27.21% in a month but still showing steep declines over 1 year and longer, is the market overlooking value in a diversified global biotech, or already factoring in any potential future growth recovery? AdvertisementMost Popular Narrative: 24% Undervalued According to the most followed narrative on CSL, the stock trading around A$117.75 is being compared with a fair value anchor of about A$155, which frames the recent volatility very differently from the share price chart alone.  CSL is cheap by almost every measure. The market is currently paying 18.7x earnings for a business that has historically traded at 28 to 30x and sits in a sector where its peers average 36x. That gap exists because FY2026 earnings are distorted by one-off restructuring charges not because the underlying business has deteriorated.  Read the complete narrative. This narrative hinges on how quickly earnings rebound once one off charges wash through. It leans on stronger profit growth, steadier margins and a valuation anchor well above today’s price. The full story sets out a specific path where current sentiment and the implied long term cash generation do not quite line up. Result: Fair Value of A$155 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, CSL still carries clear pressure points. The Tavneos decision and execution risk around the CSL Vifor restructuring are both capable of unsettling confidence in any recovery story. Find out about the key risks to this CSL narrative. Another View on CSL Using Market Multiples While the CSL narrative leans heavily on a fair value of A$155, the current P/E of 28x paints a different picture. It sits above both the Australian biotech peer average of 26.7x and the global biotech average of 25.2x, even though the last year included large one off losses and profit margins slipping from 18% to 9.1%. At the same time, the estimated fair ratio for CSL is 48.6x, far above where the stock trades today. That gap suggests investors are either still pricing in earnings risk or being cautious about how quickly profits normalise. This raises a simple question: is the share price cheap, or are expectations for a clean recovery still too high? See what the numbers say about this price — find out in our valuation breakdown. ASX:CSL P/E Ratio as at Jul 2026Next Steps With CSL caught between concern about risks and interest in potential rewards, it makes sense to act quickly and stress test the numbers yourself. To weigh both sides in one place, take a close look at the 2 key rewards and 4 important warning signs Looking for more investment ideas beyond CSL? If CSL has your attention, do not stop there. Fresh ideas often come from comparing it with very different stocks that still meet clear quality or income rules.  Target potential mispricing by scanning 7 high quality undervalued stocks that combine quality fundamentals with share prices that sit below their implied worth. Strengthen the foundation of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (20 results) that prioritise robust finances and resilience when conditions change. Put your cash to work with income focused opportunities in 5 dividend fortresses that emphasise higher yielding companies with consistent payout records.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648021795","isCrawlerRequest":true}